BREAKING: Anteris Technologies Global Corp (ASX: AVR) has just announced a monumental capital raise of US$320 million, leading to a staggering 50% surge in its share value. The new shares, priced at US$5.75 each, will elevate the company’s market size by more than 60%, significantly exceeding its current ASX valuation of US$370 million and NASDAQ listing of US$394 million.
This urgent development comes after Anteris secured a key investment from Medtronic Plc (NASDAQ: MDT), the world’s largest medical technology firm, contributing US$90 million to the funding. In a statement released today, Anteris emphasized the alignment in vision with Medtronic, aiming to innovate within the Transcatheter Aortic Valve Replacement (TAVR) market while upholding rigorous standards for patient outcomes.
CEO Wayne Paterson expressed confidence, stating, “This strategic investment represents an important milestone for our company and validates our program from the capital markets.” The capital raise is expected to bolster Anteris’s efforts to advance its innovative products, particularly the DurAVR THV System, which is currently undergoing the Paradigm clinical trial.
The funds raised will accelerate the Paradigm trial, which compares the DurAVR system against existing TAVR devices for patients suffering from severe aortic stenosis. This trial is crucial for gaining further regulatory approvals and enhancing patient care.
Medtronic’s Vice President, Jorie Sokin, acknowledged Anteris’s pioneering role in TAVR technology, stating, “Our investment in differentiated innovation like the DurAVR THV technology is core to our commitment to drive the future of TAVR.” This partnership not only marks a significant financial boost for Anteris but also lays the groundwork for future collaborations in the heart health sector.
As of this morning, Anteris shares were trading up by 5.5% at $9.40, signaling strong market confidence.
Investors are closely watching how this capital infusion will impact Anteris’s clinical efforts and market position. The company, founded in Australia, also has a significant operational presence in Minneapolis, fostering its commitment to delivering innovative solutions for structural heart disease.
Expect ongoing updates as Anteris Technologies embarks on this critical phase of growth and innovation in the heart tech industry. Share this urgent news and follow for more developments on this groundbreaking story.
